Reinventing Meniscus Treatments

OrthoPreserve was founded in 2021 by a team of orthopedic clinicians and biomedical engineers whose focus is to bring a new meniscus injury treatment to the patients in need: a replacement implant. The implant was developed at one of the top Engineering institutions in the United States by one of OrthoPreserve’s founders, where significant testing demonstrated that it’s functional performance matches natural meniscus tissue. OrthoPreserve was awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) in 2023, which has allowed for continued research and development of the implant.

We know from scientific evidence, as well as our team’s clinical experience, that meniscus injuries present a major treatment challenge. Since the meniscus has limited healing ability, the current standard of care is to cut out the damaged tissue (a meniscectomy). The loss of the meniscus in a knee can lead to persistent pain, impaired range of motion, and the early onset of arthritis. OrthoPreserve’s meniscus implant is intended to replace the removed meniscus to relieve symptoms and prevent the accelerated joint degeneration that would normally accompany a meniscectomy.

Ultimately, our mission is to help patients delay arthritis and the need for a total knee replacement with a far less invasive alternative - OrthoPreserve’s meniscus implant - that will keep them active and pain-free for years after a meniscal injury.